The ranks of Rybrevant challengers swell
The line-up is revealed to include Merck & Co and J&J itself.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
A first test of OnKure’s mutant-specific gamble
A phase 1 study of OKI-219 reads out imminently.
Two more companies try to outdo Rybrevant
After Genmab’s exit two more ADCs enter human trials.
HengRui spreads its SERD
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
Two more in vivo Cars head for the clinic
New first-in-human study initiations feature yet more in vivo Car assets.
Moderna investors prepare for a phase 3 reveal
Intismeran autogene’s Interpath-001 trial reads out this year.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
